4//SEC Filing
MATTINGLY MARTIN A 4
Accession 0001209191-17-047588
CIK 0000949858other
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 8:54 PM ET
Size
15.4 KB
Accession
0001209191-17-047588
Insider Transaction Report
Form 4
MATTINGLY MARTIN A
Director
Transactions
- Award
Stock Option (right to buy)
2017-08-01+11,000→ 11,000 totalExercise: $4.57From: 2018-08-01Exp: 2027-08-01→ Common Stock (11,000 underlying)
Holdings
- 500
Stock Option (right to buy)
Exercise: $156.20Exp: 2020-06-08→ Common Stock (500 underlying) - 363
Stock Option (right to buy)
Exercise: $138.16Exp: 2022-05-31→ Common Stock (363 underlying) - 454
Stock Option (right to buy)
Exercise: $39.82Exp: 2024-06-05→ Common Stock (454 underlying) - 2,045
Stock Option (right to buy)
Exercise: $11.00Exp: 2026-05-26→ Common Stock (2,045 underlying) - 954
Common Stock
- 318
Stock Option (right to buy)
Exercise: $196.02Exp: 2021-05-26→ Common Stock (318 underlying) - 454
Stock Option (right to buy)
Exercise: $118.03Exp: 2023-05-24→ Common Stock (454 underlying) - 454
Stock Option (right to buy)
Exercise: $20.79Exp: 2025-05-21→ Common Stock (454 underlying)
Footnotes (2)
- [F1]Reflects the 11-for-1 reverse stock split effected on August 1, 2017 immediately following the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc.
- [F2]The options are fully vested and exercisable.
Documents
Issuer
ACHIEVE LIFE SCIENCES, INC.
CIK 0000949858
Entity typeother
Related Parties
1- filerCIK 0001265782
Filing Metadata
- Form type
- 4
- Filed
- Aug 2, 8:00 PM ET
- Accepted
- Aug 3, 8:54 PM ET
- Size
- 15.4 KB